Last reviewed · How we verify
silicon gel
Silicon gel forms a protective barrier on the skin surface to reduce scar appearance and improve skin hydration.
Silicon gel forms a protective barrier on the skin surface to reduce scar appearance and improve skin hydration. Used for Hypertrophic scars, Keloid scars, Post-surgical scars.
At a glance
| Generic name | silicon gel |
|---|---|
| Also known as | Kelodacyn |
| Sponsor | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. |
| Drug class | Topical scar treatment / silicone-based dermatological product |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Silicon gel products work by creating an occlusive layer that hydrates the stratum corneum and flattens scar tissue through sustained moisture and gentle compression. The gel is typically applied topically to hypertrophic or keloid scars, where it helps normalize collagen remodeling and reduce erythema over time.
Approved indications
- Hypertrophic scars
- Keloid scars
- Post-surgical scars
Common side effects
- Local skin irritation
- Contact dermatitis
- Mild erythema at application site
Key clinical trials
- A Comparative Evaluation of the Role of Self-Adhesive Flowable Composite in Enhancing Sealant Retention Versus Conventional Pits and Fissure Sealant With and Without Fissurotomy in Permanent Molars (NA)
- Evaluation of the Scar Healing Effects of ChitoCare Medical Scar Healing Gel in Women Undergoing Breast Reduction or Mastopexy Surgery (CHITOSCAR) (NA)
- Clinical Assessment of Giomer Based Technology Versus Smart Bioactive Restoration in Carious Class V Cavities (NA)
- Comparison of the Additional Effects of Using TENS and Interferential Currents for the Treatment of Individuals With Chronic Nonspecific Neck Pain. (NA)
- ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHT
- Silicone vs Pirfenidone in the Treatment of Hypertrophic Scars and Keloids (PHASE3)
- Effect of Bioptron on Scar Formation After Cesarean Section (NA)
- StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: